ONCE - Spark Therapeutics Inc

Discussion in 'Stock Message Boards NYSE, NASDAQ, AMEX' started by StockJock-e, Aug 2, 2017.

  1. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    9,524
    Likes Received:
    3,526
    Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include voretigene neparvovec, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or biallelic mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. The company's products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A. In addition, its product candidates and development programs include SPK-FVIII program to treat hemophilia A; SPK-TPP1 program for the treatment of a form of Batten disease and Huntington's disease; RhoNova for the treatment of rhodopsin-linked autosomal dominant retinitis pigmentosa; and SPK-LHON for treating Leber hereditary optic neuropathy, as well as preclinical programs in development for the treatment of rare genetic blinding conditions, hematologic disorders, and other neurodegenerative diseases. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.

    [​IMG]
     
  2. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    9,524
    Likes Received:
    3,526
    PHILADELPHIA (AP) _ Spark Therapeutics Inc. (ONCE) on Wednesday reported a loss of $74.4 million in its second quarter.

    On a per-share basis, the Philadelphia-based company said it had a loss of $2.40. Losses, adjusted for asset impairment costs, came to $1.89 per share.

    The results fell short of Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for a loss of $1.75 per share.

    The gene therapy developer posted revenue of $1.5 million in the period, topping Street forecasts. Five analysts surveyed by Zacks expected $1.3 million.

    Spark Therapeutics shares have climbed 33 percent since the beginning of the year. The stock has risen 13 percent in the last 12 months.
     
  3. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    9,524
    Likes Received:
    3,526
    How's that for a crazy two days?

    Sell off yesterday, then does a gap higher and +20% today.

    Anybody that shaken out yesterday is kicking themselves!
     
  4. fireopal

    fireopal Well-Known Member

    Joined:
    Apr 18, 2016
    Messages:
    2,278
    Likes Received:
    517
    FDA Advisory Committee Unanimously Recommends Approval of Investigational LUXTURNAâ„¢ (voretigene neparvovec) for Patients with Biallelic RPE65-mediated Inherited Retinal Disease -https://finance.yahoo.com/news/fda-advisory-committee-unanimously-recommends-205135353.html
     
  5. MiguelHammond10

    Joined:
    Jun 12, 2017
    Messages:
    92
    Likes Received:
    5
    it's 100+ open
     
  6. rg7803

    rg7803 Well-Known Member

    Joined:
    Apr 3, 2016
    Messages:
    577
    Likes Received:
    416
    Lets see how it opens.
    In Europe up 120% after Roche pharm lab made a bid.
     

Share This Page